State of New Jersey Common Pension Fund D Sells 8,583 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

State of New Jersey Common Pension Fund D lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 14.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,792 shares of the company’s stock after selling 8,583 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.07% of IDEAYA Biosciences worth $1,818,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in IDEAYA Biosciences by 13.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 496,456 shares of the company’s stock valued at $17,664,000 after acquiring an additional 59,100 shares in the last quarter. Campbell & CO Investment Adviser LLC boosted its position in IDEAYA Biosciences by 93.2% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 61,226 shares of the company’s stock valued at $2,178,000 after acquiring an additional 29,536 shares in the last quarter. First Light Asset Management LLC bought a new stake in IDEAYA Biosciences during the 4th quarter valued at $12,299,000. Superstring Capital Management LP bought a new stake in IDEAYA Biosciences during the 4th quarter valued at $8,941,000. Finally, Vanguard Group Inc. boosted its position in IDEAYA Biosciences by 17.0% during the 4th quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company’s stock valued at $123,668,000 after acquiring an additional 504,275 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

IDYA has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, August 7th. Lifesci Capital upgraded IDEAYA Biosciences to a “strong-buy” rating in a report on Monday, July 29th. Oppenheimer decreased their price objective on IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price objective on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, Stifel Nicolaus increased their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Twelve analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Buy” and an average target price of $56.20.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $33.73 on Tuesday. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -16.78 and a beta of 0.84. The business has a fifty day moving average of $38.76 and a 200 day moving average of $39.58. IDEAYA Biosciences, Inc. has a 1 year low of $23.41 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same period in the previous year, the business posted ($0.50) earnings per share. As a group, equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.51 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.